BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35389189)

  • 1. Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer.
    Ye L; Rünger D; Angarita SA; Hadaya J; Baker JL; Lee MK; Thompson CK; Attai DJ; DiNome ML
    Breast Cancer Res Treat; 2022 Jun; 193(2):429-436. PubMed ID: 35389189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Burden of Nodal Disease for Breast Cancer Patients with Clinically Positive Nodes: Hope for More Limited Axillary Surgery.
    Angarita S; Ye L; Rünger D; Hadaya J; Baker JL; Dawson N; Thompson CK; Lee MK; Attai DJ; DiNome ML
    Ann Surg Oncol; 2021 May; 28(5):2609-2618. PubMed ID: 33084993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palpable Adenopathy Does Not Indicate High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer.
    Crown A; Sevilimedu V; Morrow M
    Ann Surg Oncol; 2021 Oct; 28(11):6060-6068. PubMed ID: 33876360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
    Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease.
    Ensenyat-Mendez M; Rünger D; Orozco JIJ; Le J; Baker JL; Weidhaas J; Marzese DM; DiNome ML
    Ann Surg Oncol; 2022 Aug; 29(8):4716-4724. PubMed ID: 35397740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
    Tvedskov TF
    Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of additional lymph node involvement in breast cancer patients with positive sentinel lymph nodes.
    Pohlodek K; Bozikova S; Meciarova I; Mucha V; Bartova M; Ondrias F
    Neoplasma; 2016; 63(3):427-34. PubMed ID: 26925789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary dissection in patients with preoperative positive nodal cytology: Genuine need or overtreatment?
    Liberale V; Rosso R; Arisio R; D'Alonzo M; Villasco A; Fuso L; De Sanctis C; Modaffari P; Biglia N
    Breast J; 2020 Feb; 26(2):168-175. PubMed ID: 31448500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer.
    Saidi RF; Dudrick PS; Remine SG; Mittal VK
    Am Surg; 2004 Feb; 70(2):101-5; discussion 105. PubMed ID: 15011910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical utility of combining pre-operative axillary ultrasonography and fine needle aspiration cytology with radionuclide guided sentinel lymph node biopsy in breast cancer patients with palpable axillary lymph nodes.
    Usmani S; Ahmed N; Al Saleh N; abu Huda F; Amanguno HG; Amir T; al Kandari F
    Eur J Radiol; 2015 Dec; 84(12):2515-20. PubMed ID: 26474908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.
    Ebner F; Wöckel A; Janni W; Kreienberg R; Schwentner L; Wischnewsky M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1823-1831. PubMed ID: 28439713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer.
    Choi SH; Barsky SH; Chang HR
    Breast J; 2003; 9(3):153-62. PubMed ID: 12752622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
    Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
    BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.